Reduction-Based Creative Telescoping for Definite Summation of D-finite Functions

Creative telescoping is an algorithmic method initiated by Zeilberger to compute definite sums by synthesizing summands that telescope, called certificates. We describe a creative telescoping algorithm that computes telescopers for definite sums of D-finite functions as well as the associated certificates in a compact form. The algorithm relies on a discrete analogue of the generalized Hermite reduction, or equivalently, a generalization of the Abramov-Petkov\v sek reduction. We provide a Maple implementation with good timings on a variety of examples.Comment: 15 page

Cognitive Impairment in Multiple Sclerosis With Regards to Disease Duration and Clinical Phenotypes

The relationships between cognitive impairment that exist during the clinical course of multiple sclerosis (MS) remain poorly described. The effect of disease duration has been studied in a few longitudinal cohorts and some cross-sectional studies that suggest that cognitive deficits tend to extend with disease duration. However, the effect of disease duration seems to be confounded by the effect of age. At the pre-clinical stage, cognitive deficits have been observed in patients with radiologically isolated syndromes, and their profile is similar than in clinically isolated syndromes (CIS) and relapsing-remitting MS (RRMS). The frequency of cognitive impairment tends to be higher in RRMS than in CIS. In these phenotypes, slowness of information processing speed (IPS) and episodic verbal and visuo-spatial memory deficits are frequently observed, but executive functions, and in particular verbal fluency, could also be impaired. More frequent and severe deficits are reported in SPMS than in RRMS with more severe deficits for memory tests, working memory and IPS. Similarly to what is observed in SPMS, patients with primary progressive MS (PPMS) present with a wide range of cognitive deficits in IPS, attention, working memory, executive functions, and verbal episodic memory with more tests and domains impaired than RRMS patients. Altogether these data suggested that not only the duration of the disease and age play an important role in the cognitive profile of patients, but also the phenotype itself, probably because of its specific pathological mechanism

Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study

Cladribine tablets; Multiple sclerosis; Quality of lifePastilles de cladribina; Esclerosi múltiple; Qualitat de vidaPastillas de cladribina; Esclerosis múltiple; Calidad de vidaBackground: Multiple sclerosis (MS) negatively affects health-related quality of life (HRQoL). Objective: To evaluate HRQoL in people with highly active relapsing MS treated with cladribine tablets (CladT; 3.5 mg/kg cumulative dose over 2 years) in CLARIFY-MS. Methods: Changes in the MS quality of life (MSQoL)-54 scores were analysed using a repeated mixed-effects linear model. Subgroup analyses were performed for participants who were pretreatment-naïve and those pretreated with disease-modifying therapies (DMTs) before initiating CladT. Safety and tolerability of CladT were also assessed. Results: MSQoL-54 physical (mean change = 4.86; 95% confidence interval (CI) = 3.18, 6.53) and mental health (4.80; 95% CI = 3.13, 6.46) composite scores (primary endpoints) showed significant improvement at Month 24 versus Baseline (p < 0.0001). Changes in the MSQoL-54 scores were consistent across the pretreatment-naïve and DMT-pretreated subgroups. No new severe or opportunistic infections occurred. Most post-baseline lymphopenia events were Grade 1–2 in severity. Transient Grade-3 lymphopenia was observed in 19.7% (95/482) of participants. Grade-4 lymphopenia was not observed. Conclusions: CladT treatment significantly improved the mean MSQoL-54 physical and mental health composite scores over 2 years. CladT efficacy in HRQoL, relapse rates and Expanded Disability Status Scale scores demonstrates its multidimensional effects in MS treatment.This work was supported by Merck (CrossRef Funder ID: 10.13039/100009945)

Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis

Cladribine tablets; Relapsing multiple sclerosis; Treatment satisfactionComprimidos de cladribina; Esclerosis múltiple recurrente; Satisfacción con el tratamientoComprimits de cladribina; Esclerosi múltiple recurrent; Satisfacció amb el tractamentBackground Multiple sclerosis (MS) is a chronic disabling disease that is associated with negative effects on health-related quality of life (HRQoL) due to reduced physical and psychosocial functioning. Cladribine tablets 10 mg (3.5 mg/kg cumulative dose over 2 years) have been approved for the treatment of adult patients with highly active relapsing multiple sclerosis (RMS). The ongoing CLARIFY-MS study (NCT03369665; EudraCT number: 2017-002632-17) aims to assess the effect of cladribine tablets 3.5 mg/kg on HRQoL of patients with highly active RMS. Objective To report on the design of the CLARIFY-MS study, baseline patient characteristics, and results of a pre-planned interim analysis focusing on treatment satisfaction, safety, and tolerability that includes all data reported till 6 months after start of treatment. Methods The CLARIFY-MS study is a 2-year, open-label, single-arm, prospective, multicenter, phase IV study. Eligible patients with highly active RMS were assigned to receive cladribine tablets 3.5 mg/kg over 2 years. Treatment satisfaction was assessed using the Treatment Satisfaction Questionnaire for Medication (TSQM, v1.4; scale range from 0 to 100, higher values indicating higher satisfaction). Safety assessments, including occurrence of treatment-emergent adverse events (TEAEs; any adverse event reported after drug administration), serious adverse events (SAEs), and lymphocyte counts, were summarized descriptively. Results A total of 482 patients from 85 sites in Europe were treated with cladribine tablets. Mean patient age was 37.4 years, 338 (70.1%) were women, median EDSS was 2.5, and 345 (71.6%) were prior users of disease-modifying therapy (DMT). During the first 6 months after the start of treatment, and before reaching the full dose of cladribine tablets, mean TSQM global satisfaction score for the overall population was 70.4 (standard deviation, ± 18.48). The side effects score was 91.9 (± 17.68), convenience scored 86.6 (± 13.57), and effectiveness was 65.8 (± 21.14). A total of 275 patients (57.1%) reported at least one TEAE and 9 patients (1.9%) had a SAE. The majority of observed lymphopenia cases were of grade 1 or 2; 33 (6.8%) of the total study cohort had grade 3 lymphopenia, and no grade 4 lymphopenia was reported. Conclusion Patients reported high treatment satisfaction (TSQM) with cladribine tablets in this pre-planned interim analysis at 6 months. Few serious, and no unexpected, adverse events were reported, and there were no instances of grade 4 lymphopenia over the first 6 months. These preliminary data indicate good tolerability and convenience of administration of cladribine tablets in patients with highly active RMS.This study was sponsored by Merck Healthcare KGaA, Darmstadt, German

Differential aquaporin 4 expression during edema build-up and resolution phases of brain inflammation

<p>Abstract</p> <p>Background</p> <p>Vasogenic edema dynamically accumulates in many brain disorders associated with brain inflammation, with the critical step of edema exacerbation feared in patient care. Water entrance through blood-brain barrier (BBB) opening is thought to have a role in edema formation. Nevertheless, the mechanisms of edema resolution remain poorly understood. Because the water channel aquaporin 4 (AQP4) provides an important route for vasogenic edema resolution, we studied the time course of AQP4 expression to better understand its potential effect in countering the exacerbation of vasogenic edema.</p> <p>Methods</p> <p>Focal inflammation was induced in the rat brain by a lysolecithin injection and was evaluated at 1, 3, 7, 14 and 20 days using a combination of in vivo MRI with apparent diffusion coefficient (ADC) measurements used as a marker of water content, and molecular and histological approaches for the quantification of AQP4 expression. Markers of active inflammation (macrophages, BBB permeability, and interleukin-1β) and markers of scarring (gliosis) were also quantified.</p> <p>Results</p> <p>This animal model of brain inflammation demonstrated two phases of edema development: an initial edema build-up phase during active inflammation that peaked after 3 days (ADC increase) was followed by an edema resolution phase that lasted from 7 to 20 days post injection (ADC decrease) and was accompanied by glial scar formation. A moderate upregulation in AQP4 was observed during the build-up phase, but a much stronger transcriptional and translational level of AQP4 expression was observed during the secondary edema resolution phase.</p> <p>Conclusions</p> <p>We conclude that a time lag in AQP4 expression occurs such that the more significant upregulation was achieved only after a delay period. This change in AQP4 expression appears to act as an important determinant in the exacerbation of edema, considering that AQP4 expression is insufficient to counter the water influx during the build-up phase, while the second more pronounced but delayed upregulation is involved in the resolution phase. A better pathophysiological understanding of edema exacerbation, which is observed in many clinical situations, is crucial in pursuing new therapeutic strategies.</p

Regional hippocampal vulnerability in early multiple sclerosis: a dynamic pathological spreading from dentate gyrus to CA1

"This is the peer reviewed version of the following article: Planche, V., Koubiyr, I., Romero, J. E., Manjon, J. V., Coupé, P., Deloire, M., ... & Tourdias, T. (2018). Regional hippocampal vulnerability in early multiple sclerosis: Dynamic pathological spreading from dentate gyrus to CA 1. Human brain mapping, 39(4), 1814-1824., which has been published in final form at https://doi.org/10.1002/hbm.23970. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving."[EN] Background: Whether hippocampal subfields are differentially vulnerable at the earliest stages of multiple sclerosis (MS) and how this impacts memory performance is a current topic of debate. Method: We prospectively included 56 persons with clinically isolated syndrome (CIS) suggestive of MS in a 1-year longitudinal study, together with 55 matched healthy controls at baseline. Participants were tested for memory performance and scanned with 3T MRI to assess the volume of 5 distinct hippocampal subfields using automatic segmentation techniques. Results: At baseline, CA4/dentate gyrus was the only hippocampal subfield with a volume significantly smaller than controls (p < .01). After one year, CA4/dentate gyrus atrophy worsened (-6.4%, p < .0001) and significant CA1 atrophy appeared (both in the stratum-pyramidale and the stratum radiatum-lacunosum-moleculare, -5.6%, p < .001 and -6.2%, p < .01, respectively). CA4/dentate gyrus volume at baseline predicted CA1 volume one year after CIS (R-2 = 0.44 to 0.47, p < .001, with age, T2 lesion-load, and global brain atrophy as covariates). The volume of CA4/dentate gyrus at baseline was associated with MS diagnosis during follow-up, independently of T2-lesion load and demographic variables (p < .05). Whereas CA4/dentate gyrus volume was not correlated with memory scores at baseline, CA1 atrophy was an independent correlate of episodic verbal memory performance one year after CIS (beta = 0.87, p < .05). Conclusion: The hippocampal degenerative process spread from dentate gyrus to CA1 at the earliest stage of MS. This dynamic vulnerability is associated with MS diagnosis after CIS and will ultimately impact hippocampal-dependent memory performance.ARSEP Foundation; Bordeaux University Hospital; TEVA Laboratories; French Agence Nationale de la Recherche, Grant/Award Numbers: ANR-10-LABX-57, ANR-10-LABX-43, ANR-10-IDEX-03-02, ANR-10-COHO-002; UPV, Grant/Award Numbers: UPV2016-0099, TIN2013-43457-R; Ministerio de Economia y competitividadPlanche, V.; Koubiyr, I.; Romero Gómez, JE.; Manjón Herrera, JV.; Coupe, P.; Deloire, M.; Dousset, V.... (2018). Regional hippocampal vulnerability in early multiple sclerosis: a dynamic pathological spreading from dentate gyrus to CA1. Human Brain Mapping. 39(4):1814-1824. https://doi.org/10.1002/hbm.23970S18141824394Avants, B. B., Tustison, N. J., Song, G., Cook, P. A., Klein, A., & Gee, J. C. (2011). A reproducible evaluation of ANTs similarity metric performance in brain image registration. NeuroImage, 54(3), 2033-2044. doi:10.1016/j.neuroimage.2010.09.025Bakker, A., Kirwan, C. B., Miller, M., & Stark, C. E. L. (2008). Pattern Separation in the Human Hippocampal CA3 and Dentate Gyrus. Science, 319(5870), 1640-1642. doi:10.1126/science.1152882Coupé, P., Manjón, J. V., Chamberland, M., Descoteaux, M., & Hiba, B. (2013). Collaborative patch-based super-resolution for diffusion-weighted images. NeuroImage, 83, 245-261. doi:10.1016/j.neuroimage.2013.06.030De Stefano, N., Airas, L., Grigoriadis, N., Mattle, H. P., O’Riordan, J., Oreja-Guevara, C., … Kieseier, B. C. (2014). Clinical Relevance of Brain Volume Measures in Multiple Sclerosis. CNS Drugs, 28(2), 147-156. doi:10.1007/s40263-014-0140-zDu, A. T., Schuff, N., Kramer, J. H., Ganzer, S., Zhu, X. P., Jagust, W. J., … Weiner, M. W. (2004). Higher atrophy rate of entorhinal cortex than hippocampus in AD. Neurology, 62(3), 422-427. doi:10.1212/01.wnl.0000106462.72282.90Dutta, R., Chang, A., Doud, M. K., Kidd, G. J., Ribaudo, M. V., Young, E. A., … Trapp, B. D. (2011). Demyelination causes synaptic alterations in hippocampi from multiple sclerosis patients. Annals of Neurology, 69(3), 445-454. doi:10.1002/ana.22337De Flores, R., La Joie, R., & Chételat, G. (2015). Structural imaging of hippocampal subfields in healthy aging and Alzheimer’s disease. Neuroscience, 309, 29-50. doi:10.1016/j.neuroscience.2015.08.033Fraser, M. A., Shaw, M. E., & Cherbuin, N. (2015). A systematic review and meta-analysis of longitudinal hippocampal atrophy in healthy human ageing. NeuroImage, 112, 364-374. doi:10.1016/j.neuroimage.2015.03.035Frisoni, G. B., Ganzola, R., Canu, E., Rub, U., Pizzini, F. B., Alessandrini, F., … Thompson, P. M. (2008). Mapping local hippocampal changes in Alzheimer’s disease and normal ageing with MRI at 3 Tesla. Brain, 131(12), 3266-3276. doi:10.1093/brain/awn280Gold, S. M., Kern, K. C., O’Connor, M.-F., Montag, M. J., Kim, A., Yoo, Y. S., … Sicotte, N. L. (2010). Smaller Cornu Ammonis 2–3/Dentate Gyrus Volumes and Elevated Cortisol in Multiple Sclerosis Patients with Depressive Symptoms. Biological Psychiatry, 68(6), 553-559. doi:10.1016/j.biopsych.2010.04.025Habbas, S., Santello, M., Becker, D., Stubbe, H., Zappia, G., Liaudet, N., … Volterra, A. (2015). Neuroinflammatory TNFα Impairs Memory via Astrocyte Signaling. Cell, 163(7), 1730-1741. doi:10.1016/j.cell.2015.11.023Hulst, H. E., Schoonheim, M. M., Van Geest, Q., Uitdehaag, B. M., Barkhof, F., & Geurts, J. J. (2015). Memory impairment in multiple sclerosis: Relevance of hippocampal activation and hippocampal connectivity. Multiple Sclerosis Journal, 21(13), 1705-1712. doi:10.1177/1352458514567727Jack, C. R., Petersen, R. C., Xu, Y., O’Brien, P. C., Smith, G. E., Ivnik, R. J., … Kokmen, E. (2000). Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology, 55(4), 484-490. doi:10.1212/wnl.55.4.484Jack, C. R., Barkhof, F., Bernstein, M. A., Cantillon, M., Cole, P. E., DeCarli, C., … Foster, N. L. (2011). Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer’s disease. Alzheimer’s & Dementia, 7(4), 474-485.e4. doi:10.1016/j.jalz.2011.04.007Kerchner, G. A., Bernstein, J. D., Fenesy, M. C., Deutsch, G. K., Saranathan, M., Zeineh, M. M., & Rutt, B. K. (2013). Shared Vulnerability of Two Synaptically-Connected Medial Temporal Lobe Areas to Age and Cognitive Decline: A Seven Tesla Magnetic Resonance Imaging Study. Journal of Neuroscience, 33(42), 16666-16672. doi:10.1523/jneurosci.1915-13.2013La Joie, R., Fouquet, M., Mézenge, F., Landeau, B., Villain, N., Mevel, K., … Chételat, G. (2010). Differential effect of age on hippocampal subfields assessed using a new high-resolution 3T MR sequence. NeuroImage, 53(2), 506-514. doi:10.1016/j.neuroimage.2010.06.024Longoni, G., Rocca, M. A., Pagani, E., Riccitelli, G. C., Colombo, B., Rodegher, M., … Filippi, M. (2013). Deficits in memory and visuospatial learning correlate with regional hippocampal atrophy in MS. Brain Structure and Function, 220(1), 435-444. doi:10.1007/s00429-013-0665-9Manjón, J. V., & Coupé, P. (2016). volBrain: An Online MRI Brain Volumetry System. Frontiers in Neuroinformatics, 10. doi:10.3389/fninf.2016.00030Manjón, J. V., Coupé, P., Martí-Bonmatí, L., Collins, D. L., & Robles, M. (2009). Adaptive non-local means denoising of MR images with spatially varying noise levels. Journal of Magnetic Resonance Imaging, 31(1), 192-203. doi:10.1002/jmri.22003Manjón, J. V., Eskildsen, S. F., Coupé, P., Romero, J. E., Collins, D. L., & Robles, M. (2014). Nonlocal Intracranial Cavity Extraction. International Journal of Biomedical Imaging, 2014, 1-11. doi:10.1155/2014/820205Maruszak, A., & Thuret, S. (2014). Why looking at the whole hippocampus is not enough—a critical role for anteroposterior axis, subfield and activation analyses to enhance predictive value of hippocampal changes for Alzheimer’s disease diagnosis. Frontiers in Cellular Neuroscience, 8. doi:10.3389/fncel.2014.00095Miller, D. H., Chard, D. T., & Ciccarelli, O. (2012). Clinically isolated syndromes. The Lancet Neurology, 11(2), 157-169. doi:10.1016/s1474-4422(11)70274-5Morra, J. H., Tu, Z., Apostolova, L. G., Green, A. E., Avedissian, C., … Madsen, S. K. (2009). Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer’s disease, mild cognitive impairment, and elderly controls. Human Brain Mapping, 30(9), 2766-2788. doi:10.1002/hbm.20708Ny�l, L. G., & Udupa, J. K. (1999). On standardizing the MR image intensity scale. Magnetic Resonance in Medicine, 42(6), 1072-1081. doi:10.1002/(sici)1522-2594(199912)42:63.0.co;2-mPapadopoulos, D., Dukes, S., Patel, R., Nicholas, R., Vora, A., & Reynolds, R. (2009). Substantial Archaeocortical Atrophy and Neuronal Loss in Multiple Sclerosis. Brain Pathology, 19(2), 238-253. doi:10.1111/j.1750-3639.2008.00177.xPérez-Miralles, F., Sastre-Garriga, J., Tintoré, M., Arrambide, G., Nos, C., Perkal, H., … Montalban, X. (2013). Clinical impact of early brain atrophy in clinically isolated syndromes. Multiple Sclerosis Journal, 19(14), 1878-1886. doi:10.1177/1352458513488231Planche, V., Ruet, A., Coupé, P., Lamargue-Hamel, D., Deloire, M., Pereira, B., … Tourdias, T. (2016). Hippocampal microstructural damage correlates with memory impairment in clinically isolated syndrome suggestive of multiple sclerosis. Multiple Sclerosis Journal, 23(9), 1214-1224. doi:10.1177/1352458516675750Planche, V., Panatier, A., Hiba, B., Ducourneau, E.-G., Raffard, G., Dubourdieu, N., … Tourdias, T. (2017). Selective dentate gyrus disruption causes memory impairment at the early stage of experimental multiple sclerosis. Brain, Behavior, and Immunity, 60, 240-254. doi:10.1016/j.bbi.2016.11.010Planche, V., Ruet, A., Charré-Morin, J., Deloire, M., Brochet, B., & Tourdias, T. (2017). Pattern separation performance is decreased in patients with early multiple sclerosis. Brain and Behavior, 7(8), e00739. doi:10.1002/brb3.739Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., … Wolinsky, J. S. (2011). Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Annals of Neurology, 69(2), 292-302. doi:10.1002/ana.22366Rocca, M. A., Longoni, G., Pagani, E., Boffa, G., Colombo, B., Rodegher, M., … Filippi, M. (2015). In vivo evidence of hippocampal dentate gyrus expansion in multiple sclerosis. Human Brain Mapping, 36(11), 4702-4713. doi:10.1002/hbm.22946Romero, J. E., Coupe, P., & Manjón, J. V. (2016). High Resolution Hippocampus Subfield Segmentation Using Multispectral Multiatlas Patch-Based Label Fusion. Lecture Notes in Computer Science, 117-124. doi:10.1007/978-3-319-47118-1_15Romero, J. E., Coupé, P., & Manjón, J. V. (2017). HIPS: A new hippocampus subfield segmentation method. NeuroImage, 163, 286-295. doi:10.1016/j.neuroimage.2017.09.049Schmidt, P., Gaser, C., Arsic, M., Buck, D., Förschler, A., Berthele, A., … Mühlau, M. (2012). An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis. NeuroImage, 59(4), 3774-3783. doi:10.1016/j.neuroimage.2011.11.032Sicotte, N. L., Kern, K. C., Giesser, B. S., Arshanapalli, A., Schultz, A., Montag, M., … Bookheimer, S. Y. (2008). Regional hippocampal atrophy in multiple sclerosis. Brain, 131(4), 1134-1141. doi:10.1093/brain/awn030Small, S. A. (2014). Isolating Pathogenic Mechanisms Embedded within the Hippocampal Circuit through Regional Vulnerability. Neuron, 84(1), 32-39. doi:10.1016/j.neuron.2014.08.030Stark, S. M., Yassa, M. A., Lacy, J. W., & Stark, C. E. L. (2013). A task to assess behavioral pattern separation (BPS) in humans: Data from healthy aging and mild cognitive impairment. Neuropsychologia, 51(12), 2442-2449. doi:10.1016/j.neuropsychologia.2012.12.014Thompson, P. M., Hayashi, K. M., de Zubicaray, G. I., Janke, A. L., Rose, S. E., Semple, J., … Toga, A. W. (2004). Mapping hippocampal and ventricular change in Alzheimer disease. NeuroImage, 22(4), 1754-1766. doi:10.1016/j.neuroimage.2004.03.040Tustison, N. J., Avants, B. B., Cook, P. A., Yuanjie Zheng, Egan, A., Yushkevich, P. A., & Gee, J. C. (2010). N4ITK: Improved N3 Bias Correction. IEEE Transactions on Medical Imaging, 29(6), 1310-1320. doi:10.1109/tmi.2010.2046908Wang, L., Swank, J. S., Glick, I. E., Gado, M. H., Miller, M. I., Morris, J. C., & Csernansky, J. G. (2003). Changes in hippocampal volume and shape across time distinguish dementia of the Alzheimer type from healthy aging☆. NeuroImage, 20(2), 667-682. doi:10.1016/s1053-8119(03)00361-6West, M. ., Coleman, P. ., Flood, D. ., & Troncoso, J. . (1994). Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer’s disease. The Lancet, 344(8925), 769-772. doi:10.1016/s0140-6736(94)92338-8Winterburn, J. L., Pruessner, J. C., Chavez, S., Schira, M. M., Lobaugh, N. J., Voineskos, A. N., & Chakravarty, M. M. (2013). A novel in vivo atlas of human hippocampal subfields using high-resolution 3T magnetic resonance imaging. NeuroImage, 74, 254-265. doi:10.1016/j.neuroimage.2013.02.003Wisse, L. E. M., Daugherty, A. M., Olsen, R. K., Berron, D., Carr, V. A., … Stark, C. E. L. (2016). A harmonized segmentation protocol for hippocampal and parahippocampal subregions: Why do we need one and what are the key goals? Hippocampus, 27(1), 3-11. doi:10.1002/hipo.22671Yushkevich, P. A., Amaral, R. S. C., Augustinack, J. C., Bender, A. R., Bernstein, J. D., Boccardi, M., … Zeineh, M. M. (2015). Quantitative comparison of 21 protocols for labeling hippocampal subfields and parahippocampal subregions in in vivo MRI: Towards a harmonized segmentation protocol. NeuroImage, 111, 526-541. doi:10.1016/j.neuroimage.2015.01.00

Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)

Background: Cognitive impairment in MS impacts negatively on many patients at all disease stages and in all subtypes. Full clinical cognitive assessment is expensive, requiring expert staff and special equipment. Test versions and normative data are not available for all languages and cultures. Objective: To recommend a brief cognitive assessment for multiple sclerosis (MS) that is optimized for small centers, with one or few staff members, who may not have neuropsychological training and constructed to maximize international use. Methods: An expert committee of twelve members representing the main cultural groups that have so far contributed considerable data about MS cognitive dysfunction was convened. Following exhaustive literature review, peer-reviewed articles were selected to cover a broad spectrum of cultures and scales that targeted cognitive domains vulnerable to MS. Each was rated by two committee members and candidates scales were rated on psychometric qualities (reliability, validity, and sensitivity), international application, ease of administration, feasibility in the specified context, and acceptability to patients. Results: The committee recommended the Symbol Digit Modalities Test, if only 5 minutes was available, with the addition of the California Verbal Learning Test – Second Edition and the Brief Visuospatial Memory Test – Revised learning trials if a further 10 minutes could be allocated for testing. Conclusions: A brief cognitive assessment for MS has been recommended. A validation protocol has been prepared for language groups and validation studies have commenced

Five years of ocrelizumab in relapsing multiple sclerosis : OPERA studies open-label extension

Objective: To assess over 3 years of follow-up the effects of maintaining or switching to ocrelizumab (OCR) therapy on clinical and MRI outcomes and safety measures in the open-label extension (OLE) phase of the pooled OPERA: I/II studies in relapsing multiple sclerosis. Methods:After 2 years of double-blind, controlled treatment, patients continued OCR (600 mg infusions every 24 weeks) or switched from interferon (IFN)-β-1a (44 g 3 times weekly) to OCR when entering the OLE phase (3 years). Adjusted annualized relapse rate, time to onset of 24-week confirmed disability progression (CDP)/improvement (CDP), brain MRI activity (gadolinium-enhanced and new/enlarging T2 lesions), and percentage brain volume change were analyzed. Results:Of patients entering the OLE phase, 88.6% completed year 5. The cumulative proportion with 24-week CDP was lower in patients who initiated OCR earlier vs patients initially receiving IFN-β-1a (16.1% vs 21.3% at year 5; p = 0.014). Patients continuing OCR maintained and those switching from IFN-β-1a to OCR attained near complete and sustained suppression of new brain MRI lesion activity from years 3-5. Over the OLE phase, patients continuing OCR exhibited less whole brain volume loss from double-blind study baseline vs those switching from IFN-β-1a (-1.87% vs-2.15% at year 5; p < 0.01). Adverse events were consistent with past reports and no new safety signals emerged with prolonged treatment.ConclusionCompared with patients switching from IFN-β-1a, earlier and continuous OCR treatment up to 5 years provided sustained benefit on clinical and MRI measures of disease progression.Classification of evidenceThis study provides Class III evidence that earlier and continuous treatment with OCR provided sustained benefit on clinical and MRI outcomes of disease activity and progression compared with patients switching from IFN-β-1a. The study is rated Class III because of the initial treatment randomization disclosure that occurred after inclusion in OLE.Clinical trial identifiersNCT01247324/NCT01412333

Measurement of double-differential cross sections for top quark pair production in pp collisions at [Formula: see text][Formula: see text] and impact on parton distribution functions.

Normalized double-differential cross sections for top quark pair ([Formula: see text]) production are measured in pp collisions at a centre-of-mass energy of 8[Formula: see text] with the CMS experiment at the LHC. The analyzed data correspond to an integrated luminosity of 19.7[Formula: see text]. The measurement is performed in the dilepton [Formula: see text] final state. The [Formula: see text] cross section is determined as a function of various pairs of observables characterizing the kinematics of the top quark and [Formula: see text] system. The data are compared to calculations using perturbative quantum chromodynamics at next-to-leading and approximate next-to-next-to-leading orders. They are also compared to predictions of Monte Carlo event generators that complement fixed-order computations with parton showers, hadronization, and multiple-parton interactions. Overall agreement is observed with the predictions, which is improved when the latest global sets of proton parton distribution functions are used. The inclusion of the measured [Formula: see text] cross sections in a fit of parametrized parton distribution functions is shown to have significant impact on the gluon distribution

Studies of Bs2∗(5840)0 and Bs1(5830)0 mesons including the observation of the Bs2∗(5840)0→B0KS0 decay in proton-proton collisions at s=8TeV.

Measurements of Bs2∗(5840)0 and Bs1(5830)0 mesons are performed using a data sample of proton-proton collisions corresponding to an integrated luminosity of , collected with the CMS detector at the LHC at a centre-of-mass energy of 8TeV . The analysis studies P-wave Bs0 meson decays into B(∗)+K- and B(∗)0KS0 , where the B+ and B0 mesons are identified using the decays B+→J/ψK+ and B0→J/ψK∗(892)0 . The masses of the P-wave Bs0 meson states are measured and the natural width of the Bs2∗(5840)0 state is determined. The first measurement of the mass difference between the charged and neutral B∗ mesons is also presented. The Bs2∗(5840)0 decay to B0KS0 is observed, together with a measurement of its branching fraction relative to the Bs2∗(5840)0→B+K- decay